Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066372
Filing Date
2025-05-08
Accepted
2025-05-08 07:14:15
Documents
78
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q glue-20250331.htm   iXBRL 10-Q 1771263
2 EX-31.1 glue-ex31_1.htm EX-31.1 19052
3 EX-32.1 glue-ex32_1.htm EX-32.1 11476
  Complete submission text file 0000950170-25-066372.txt   8290589

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT glue-20250331.xsd EX-101.SCH 1221017
80 EXTRACTED XBRL INSTANCE DOCUMENT glue-20250331_htm.xml XML 1529390
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40522 | Film No.: 25923835
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)